Jon Congleton
Chief Executive Officer at Mineralys Therapeutics Inc.
Sits on 3 boards. Last updated September 28, 2026
Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 5 years
- Director since
- 2023
5 years of board service in total across 3 boards, counting each seat separately. Longest: Mineralys Therapeutics Inc., 3 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Mineralys Therapeutics Inc. May 22, 202487.5%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 30, 2026 | Mineralys Therapeutics Inc. | Open-market sale | −75,000 | $25.46 | $1,909,665 |
| Jul 13, 2026 | Mineralys Therapeutics Inc. | Open-market sale | −10,700 | $27.24 | $291,468 |
| Jun 30, 2026 | Mineralys Therapeutics Inc. | Open-market sale | −58,000 | $25.94 | $1,504,520 |
| Jun 30, 2026 | Mineralys Therapeutics Inc. | Open-market sale | −17,000 | $26.82 | $455,940 |
| Apr 13, 2026 | Mineralys Therapeutics Inc. | Open-market sale | −15,730 | $26.83 | $422,036 |
| Mar 31, 2026 | Mineralys Therapeutics Inc. | Open-market sale | −19,364 | $25.50 | $493,782 |
| Mar 31, 2026 | Mineralys Therapeutics Inc. | Open-market sale | −55,183 | $26.54 | $1,464,557 |
| Mar 31, 2026 | Mineralys Therapeutics Inc. | Open-market sale | −453 | $27.05 | $12,254 |
| Feb 19, 2026 | Mineralys Therapeutics Inc. | Grant or award | +140,900 | — | — |
| Jan 12, 2026 | Mineralys Therapeutics Inc. | Open-market sale | −9,119 | $32.21 | $293,723 |
| Jan 12, 2026 | Mineralys Therapeutics Inc. | Open-market sale | −7,117 | $33.15 | $235,929 |
| Nov 21, 2025 | Mineralys Therapeutics Inc. | Option exercise | +24,082 | $0.54 | $13,004 |
| Nov 11, 2025 | Mineralys Therapeutics Inc. | Open-market sale | −12,806 | $41.64 | $533,242 |
| Nov 11, 2025 | Mineralys Therapeutics Inc. | Open-market sale | −8,862 | $42.31 | $374,951 |
| Nov 11, 2025 | Mineralys Therapeutics Inc. | Open-market sale | −4,000 | $43.50 | $174,000 |
Questions about Jon Congleton
What boards is Jon Congleton on?
Jon Congleton sits on the boards of Avalyn Pharma Inc., Immunic Inc. and Mineralys Therapeutics Inc.
What company is Jon Congleton the CEO of?
Jon Congleton has been Chief Executive Officer of Mineralys Therapeutics Inc. since February 2023.
How long has Jon Congleton served on boards?
Our records show at least 5 years of board service across 3 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.